NANOホールディングス will transfer its drug discovery business to a newly established subsidiary and make a full-scale entry into investment, primarily in the healthcare sector. Going forward, it aims to enhance corporate value and create exit opportunities through fund expansion centred on NBI and global expansion.
NANOホールディングス changed its corporate name to NANOホールディングス effective 11 December 2025, then changed its drug discovery business from NANOホールディングス to the newly established subsidiary NANO MRNA（株） through a company split effective 1 April 2026, transitioning to a holding company structure. Its principal business is now investment, primarily in the healthcare sector, and it is pursuing group management with NANO MRNA and other companies engaged in the drug discovery business under its umbrella.
Amid collaboration with overseas capital and government efforts to strengthen Japan's drug discovery capabilities, the company is promoting a new model that supports Japan's outstanding technologies and assets with funding and specialised personnel. It aims to enhance corporate value and create exit opportunities through the global expansion of its investee companies, licensing out and M&A.
1. It launched its new structure as a Public Strategic Investment Company and made a full-scale entry into investment, primarily in the healthcare sector. Through its subsidiary NBI, which manages the formation and operation of funds, it will provide funding and support the global expansion of its investee companies by leveraging its US-based network.
2. As a medium-term objective for its investment business, it will expand NANO Bridge I, a fund jointly managed by NBI and SBI新生グロースキャピタル, and continue launching Fund II and Fund III. It will strengthen its earnings base by monetising capital gains from the sale of investments, as well as fund management fees and performance fees.
3. While indicating a policy of pursuing maximum shareholder returns, the company will continue to disclose progress at its investee companies and their global expansion, aiming to maximise shareholder value through sustained growth in corporate value over the medium to long term. It also states that it will consider a special dividend.